Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 2/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.46 |
| ▸ | PRKCI | P41743 | 3/20 | 0.44 |
| ▸ | AXL | P30530 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.37 |
| ▸ | JAK1 | P23458 | 3/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.35 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10125092 | 0.88 | PRKCI (0.51) | CCNKCDK12PRKCIAXLJAK2 | |
| SCHEMBL10125053 | 0.80 | AXL (0.40) | CCNKCDK12PRKCIAXLJAK2 | |
| SCHEMBL12346324 | 0.78 | CCNK (0.48) | CCNKCDK12PRKCIAXLJAK2 | |
| SCHEMBL10125408 | 0.75 | CCNK (0.44) | CCNKCDK12PRKCIAXLJAK2 | |
| SCHEMBL12347998 | 0.74 | AXL (0.47) | CCNKCDK12PRKCIAXLJAK2 | |
| SCHEMBL2239821 | 0.74 | PRKCI (0.53) | CCNKCDK12PRKCIAXLJAK2 | |
| SCHEMBL1724114 | 0.73 | CCNK (0.56) | CCNKCDK12PRKCIAXLJAK2 | |
| SCHEMBL1724051 | 0.73 | CCNK (0.49) | CCNKCDK12PRKCIAXLJAK2 | |
| SCHEMBL1356886 | 0.71 | PRKCI (0.67) | CCNKCDK12PRKCIAXLJAK2 | |
| SCHEMBL858281 | 0.70 | CDK8 (0.54) | AXLJAK2RPS6KA3NUDT1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| EP-1881983-B1 | PYRROLOPYRIDINES USEFUL AS INHIBITORS OF PROTEIN KINASE | VERTEX PHARMA (US) | 2012-01-11 | — | — | EP | disclosed |
| EP-2354140-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| EP-2354139-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | Vertex Pharmaceuticals Incorporated (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | CCNK 597/4885CDK12 577/4885PRKCI 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.